Inclusion criteria: The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation.
Sponsor/Collaborator: Loxo Oncology, Inc.|Eli Lilly and Company
Contact and Locations:
There may be multiple sites in this clinical trial
Email: ClinicalTrials.gov@lilly.com
Phone Number: 1-877-CTLILLY (1-877-285-4559)
Locations: https://clinicaltrials.gov/study/NCT04819100#contacts-and-locations
Mechanism of action: Selpercatinib, also known as LOXO-292, is a highly selective and potent, oral inhibitor for the treatment of patients with cancers that harbor abnormalities in the RET kinase
Phases: Phase 3
NCT Number: NCT04819100
Status: Recruiting
